Evidence map›Paper›PMID 24668760›Full record

Trial reportDepression and anxiety2014

Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.

Rebecca B Price, Dan V Iosifescu, James W Murrough, Lee C Chang, Rayan K Al Jurdi, Syed Z Iqbal, Laili Soleimani, Dennis S Charney, Alexandra L Foulkes, Sanjay J Mathew

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Depression and anxiety, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03502551 (ED Treatment of Suicidal Patients With Ketamine Infusion), which is not on this map. Cited by 158 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 15 pooled it
29.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03502551 phase2withdrawnnot on this mapstarted 2019, after this paper: background citation

ED Treatment of Suicidal Patients With Ketamine Infusion

TypeinterventionalSponsorUniversity of California, DavisRan2019 to 2019Enrolled0ConditionsSuicide, Suicidal IdeationArmsKetamine
3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 15 syntheses or guidelines pooled it, 337 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pharmacological interventions for self-harm in adults.The Cochrane database of systematic reviews · 2015
    Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Entactogen Effects of Ketamine: A Reverse-Translational Study.The American journal of psychiatry · 2024
    Trial
  19. Trial
  20. Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2023
    Trial

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Rebecca B PriceDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Dan V Iosifescu
James W Murrough
Lee C Chang
Rayan K Al Jurdi
Syed Z Iqbal
Laili Soleimani
Dennis S Charney
Alexandra L Foulkes
Sanjay J Mathew
Icahn School of Medicine at Mount Sinai · USMichael E. DeBakey VA Medical Center · USBaylor College of Medicine · USUniversity of Pittsburgh · US

Funding

Mount Sinai Institutes for Clinical and Translational SciencesUL1TR000067 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SAMPSON, HUGH A · 2012 to 2014
$16.5M
Optimization of IV Ketamine for Treatment Resistant Major DepressionR01MH081870 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MATHEW, SANJAY J · 2009 to 2012
$1.4M
Functional MRI Studies of Emotion in Depression and Rapid Antidepressant ResponseK23MH094707 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MURROUGH, JAMES WARREN · 2011 to 2015
$911k
Neural Dimensions of Attention Bias Modification for Transdiagnostic AnxietyK23MH100259 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PRICE, REBECCA · 2013 to 2017
$788k
NCATS NIH HHS UL1 TR000067NIMH NIH HHS 1K23 MH-094707NIMH NIH HHS 1K23MH100259NIMH NIH HHS K23 MH094707NIMH NIH HHS K23 MH100259NIMH NIH HHS R01 MH-081870NIMH NIH HHS R01 MH081870
6 · The paper itself

Abstract

backgroundPreliminary evidence suggests intravenous ketamine has rapid effects on suicidal cognition, making it an attractive candidate for depressed patients at imminent risk of suicide. In the first randomized controlled trial of ketamine using an anesthetic control condition, we tested ketamine's acute effects on explicit suicidal cognition and a performance-based index of implicit suicidal cognition (Implicit Association Test; IAT) previously linked to suicidal behavior.

methodSymptomatic patients with treatment-resistant unipolar major depression (inadequate response to ≥3 antidepressants) were assessed using a composite index of explicit suicidal ideation (Beck Scale for Suicidal Ideation, Montgomery-Asberg Rating Scale suicide item, Quick Inventory of Depressive Symptoms suicide item) and the IAT to assess suicidality implicitly. Measures were taken at baseline and 24 hr following a single subanesthetic dose of ketamine (n = 36) or midazolam (n = 21), a psychoactive placebo agent selected for its similar, rapid anesthetic effects. Twenty four hours postinfusion, explicit suicidal cognition was significantly reduced in the ketamine but not the midazolam group.

resultsFifty three percent of ketamine-treated patients scored zero on all three explicit suicide measures at 24 hr, compared with 24% of the midazolam group (χ(2) = 4.6; P = .03). Implicit associations between self- and escape-related words were reduced following ketamine (P = .01; d = .58) but not midazolam (P = .68; d = .09). Ketamine-specific decreases in explicit suicidal cognition were largest in patients with elevated suicidal cognition at baseline, and were mediated by decreases in nonsuicide-related depressive symptoms.

conclusionsIntravenous ketamine produces rapid reductions in suicidal cognition over and above active placebo. Further study is warranted to test ketamine's antisuicidal effects in higher-risk samples.

Indexed as

Suicide PreventionAdultAnalgesicsAnti-Anxiety AgentsCognitionDepressive Disorder, Treatment-ResistantDouble-Blind MethodFemaleHumansKetamineMaleMidazolamMiddle AgedPsychiatric Status Rating ScalesSuicidal IdeationSuicideAnalgesicsAnti-Anxiety AgentsKetamineMidazolamantidepressantsbiological markersclinical trialsdepressionmood disorderssuicide/self-harm

Identifiers

PMID24668760
PMCPMC4112410
OpenAlexW1865092458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.